Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929417 | 0.94 | HRH3 (0.59) | HRH3ADRA1ACRBN | |
| SCHEMBL4936546 | 0.94 | HRH3 (0.64) | HRH3ADRA1AMAPTSMN1; SMN2UBE2T | |
| SCHEMBL4136446 | 0.85 | HRH3 (0.54) | HRH3ADRA1AMAPTSMN1; SMN2 | |
| SCHEMBL4130587 | 0.83 | HRH3 (0.51) | HRH3ADRA1AUBE2T | |
| SCHEMBL6117792 | 0.82 | HRH3 (0.66) | HRH3ADRA1AMAPTSMN1; SMN2 | |
| SCHEMBL14027177 | 0.82 | HRH3 (0.64) | HRH3ADRA1AUBE2T | |
| SCHEMBL4130565 | 0.82 | HRH3 (0.52) | HRH3ADRA1ASMN1; SMN2 | |
| SCHEMBL4433768 | 0.81 | ADRA1A (0.57) | HRH3ADRA1A | |
| SCHEMBL4137012 | 0.80 | HRH3 (0.55) | HRH3ADRA1ASMN1; SMN2CRBN | |
| SCHEMBL4130774 | 0.80 | ALDH1A1 (0.59) | HRH3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | HRH3 1/4885ADRA1A 420/4885MAPT 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.